QuidelOrtho Stock Soars 10.85% on Q2 Earnings Beat

On August 6, 2025, QuidelOrtho's stock surged by 10.85% in pre-market trading, reflecting a significant boost in investor confidence.

QuidelOrtho, a leading healthcare diagnostics company, reported its Q2 earnings for CY2025, meeting Wall Street's revenue expectations despite a 3.6% year-over-year decline in sales. The company's adjusted earnings per share (EPS) rebounded to $0.12, surpassing both expectations and the previous year's results on an adjusted basis. This improvement was driven by significant cost savings and restructuring efforts, which included $179 million in charges.

During the earnings call, QuidelOrtho's management highlighted that the company's EPS of $0.12 far exceeded the forecasted $0.0015, resulting in a 7900% surprise. Revenue also slightly surpassed expectations, with a 0.67% increase. The company's full-year earnings are projected to be in the range of $2.07 to $2.57 per share, with revenue expected to be between $2.6 billion and $2.81 billion.

QuidelOrtho's strong Q2 performance, coupled with its optimistic outlook for the remainder of the year, has bolstered investor confidence in the company's ability to navigate market challenges and continue delivering value to shareholders.